收藏切换
The lipid-lowering effect of sacubitril valsartan combined with rosuvastatin on patients with acute coronary syndrome after PCI and its impact on the cardiovascular outcomes
收藏切换
Xueyan NIU1, 2a, Zhiming HUANG2b, Fei CHEN2a, Haoming SONG3, *
World Clinical Drug | 2026, 47(4) : 385 - 390
Less
收藏切换
World Clinical Drug | 2026, 47(4): 385-390
• Article •
The lipid-lowering effect of sacubitril valsartan combined with rosuvastatin on patients with acute coronary syndrome after PCI and its impact on the cardiovascular outcomes
Full
Xueyan NIU1, 2a, Zhiming HUANG2b, Fei CHEN2a, Haoming SONG3, *
Affiliations
  • 1.Tongji University School of Medicine, Shanghai 200092, China
  • 2a.Department of General Practice, Shanghai Jing'an District Zhabei Central Hospital, Shanghai 200070, China
  • 2b.Department of Cardiovascular Medicine, Shanghai Jing'an District Zhabei Central Hospital, Shanghai 200070, China
  • 3.Department of General Practice, Tongji Hospital of Tongji University, Shanghai 200065, China
Published: 2026-04-10 doi: 10.13683/j.wph.2026.04.006
Outline
收藏切换
Objective

To investigate the lipid-lowering effect of sacubitril valsartan combined with rosuvastatin on patients with acute coronary syndrome(ACS) after percutaneous coronary intervention(PCI) and its impact on the cardiovascular outcomes.

Methods

A total of 121 ACS patients admitted to Shanghai Jing'an district Zhabei central hospital from January 2021 to December 2024 were selected as the research subjects. They were divided into the case group(61 cases) and the control group(60 cases) according to the treatment methods. Both groups underwent PCI and received aspirin combined with clopidogrel. The control group was given rosuvastatin, while the case group was given sacubitril valsartan combined with rosuvastatin. Both groups were treated for 2 months. The clinical efficacy, lipid levels, myocardial injury conditions, cardiac function, and the occurrence of adverse cardiovascular events were compared between the two groups.

Results

After treatment, the total clinical effective rate of the case group was higher than that of the control group(91.80% vs. 75.00%, P<0.05). After treatment, the total cholesterol, triglycerides, low-density lipoprotein cholesterol, N-terminal pro-B-type natriuretic peptide, creatine kinase-MB, and cardiac troponin I levels, as well as the left ventricular end-diastolic diameter, left ventricular end-systolic diameter, and interventricular septal thickness, were all lower than those before treatment in both groups(P<0.05), and those of the case group were lower than those of the control group(P<0.05), the high-density lipoprotein cholesterol levels of both groups were higher than those before treatment, and the case group was higher than the control group(P<0.05). The incidence of adverse cardiovascular events in the case group was lower than that in the control group(4.92% vs. 16.67%, P<0.05).

Conclusion

Sacubitril valsartan combined with rosuvastatin can effectively regulate lipid indicators in ACS patients after PCI and has a positive effect on the long-term cardiovascular outcome.

sacubitril valsartan  /  rosuvastatin  /  acute coronary syndrome  /  percutaneous coronary intervention  /  blood lipid
牛雪艳, 黄志铭, 陈斐, 宋浩明. 沙库巴曲缬沙坦联合瑞舒伐他汀对PCI术后急性冠脉综合征患者降脂效果及对心血管结局的影响. 世界临床药物, 2026 , 47 (4) : 385 -390 . DOI: 10.13683/j.wph.2026.04.006
Xueyan NIU, Zhiming HUANG, Fei CHEN, Haoming SONG. The lipid-lowering effect of sacubitril valsartan combined with rosuvastatin on patients with acute coronary syndrome after PCI and its impact on the cardiovascular outcomes[J]. World Clinical Drug, 2026 , 47 (4) : 385 -390 . DOI: 10.13683/j.wph.2026.04.006
Year 2026 volume 47 Issue 4
44
11
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.04.006
  • Receive Date:2025-06-28
  • Online Date:2026-11-05
  • Published:2026-04-10
Article Data
Affiliations
History
  • Received:2025-06-28
  • Revised:2026-02-12
Affiliations
    1.Tongji University School of Medicine, Shanghai 200092, China
    2a.Department of General Practice, Shanghai Jing'an District Zhabei Central Hospital, Shanghai 200070, China
    2b.Department of Cardiovascular Medicine, Shanghai Jing'an District Zhabei Central Hospital, Shanghai 200070, China
    3.Department of General Practice, Tongji Hospital of Tongji University, Shanghai 200065, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.04.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT